Certolizumab pegol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
 |
The introduction to this article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody.
It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [1]
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.
In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.
References
External links
Humanized monoclonal antibodies ("-zu-") | |
|---|---|
| "-tuzu-" (tumor) | Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin |
| "-lizu-" (immune system) | Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab |
| "-bazu-" (bacterial) | Tefibazumab |
| "-cizu-" (cardiovascular) | Bevacizumab, Tadocizumab |
| "-neuzu-" (nervous system) | Bapineuzumab |
| "-toxazu-" (toxin as target) | Urtoxazumab |
| "-vizu-" (viral infections) | Felvizumab, Motavizumab, Palivizumab, PRO 140 |
